Durham, NORTH%20CAROLINA9 Active Studies

Geographic Atrophy Clinical Trials in Durham, NORTH%20CAROLINA

Find 9 actively recruiting geographic atrophy clinical trials in Durham, NORTH%20CAROLINA. Connect with local research sites and explore new treatment options.

9
Active Trials
9
Sponsors
1,217
Enrolling

Recruiting Geographic Atrophy Studies in Durham

RecruitingDurham, NORTH%20CAROLINANCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemoth...

413 participants
AstraZeneca
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

258 participants
Phanes Therapeutics
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT06709521

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of m...

150 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT03971409

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating pat...

150 participants
Laura Huppert, MD, BA
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT06856525

Dissolved Phase HXe-129 MRI: a Novel Biomarker to Quantify Pulmonary Pathology in Young Healthy E-cigarette Users

A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of elect...

80 participants
Y. Michael Shim, MD
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT06388083

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease...

60 participants
Belite Bio, Inc
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT05956626

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either ...

51 participants
Ocugen
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT04665037

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with ...

40 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingDurham, NORTH%20CAROLINANCT05487599

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels o...

15 participants
Prevail Therapeutics
View Study Details

About Geographic Atrophy Clinical Trials in Durham

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 9 geographic atrophy clinical trials recruiting participants in Durham, NORTH%20CAROLINA. These studies are seeking a combined 1,217 participants. Research is being sponsored by AstraZeneca, Phanes Therapeutics, National Institute of Allergy and Infectious Diseases (NIAID) and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Durham — FAQ

Are there geographic atrophy clinical trials in Durham?

Yes, there are 9 geographic atrophy clinical trials currently recruiting in Durham, NORTH%20CAROLINA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Durham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you about next steps.

Are clinical trials in Durham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Durham studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 9 active trials in Durham are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov